Cancer treatment and research communications最新文献

{"title":"Accuracy of Image-guided Tru-cut biopsy in the diagnosis of breast tumors","authors":"Alya A. Al Zobair ,&nbsp;Wahda M. Al-Nauimy ,&nbsp;Sabruldeen M. Mohammed","doi":"10.1016/j.ctarc.2025.100955","DOIUrl":"10.1016/j.ctarc.2025.100955","url":null,"abstract":"<div><h3>Background</h3><div>Histopathological examination is the gold standard for the diagnosis of breast cancer. This study aims to ascertain the extent to which image-guided Tru-cut biopsy is sensitive and accurate in the diagnosis of breast cancer cases in our locality.</div></div><div><h3>Method</h3><div>This prospective study included 115 patients who presented with one or more breast lumps and suspected to be neoplastic based on the clinical and radiological assessment. All patients have been subjected to Tru-cut biopsy under ultrasound guidance to confirm or exclude the diagnosis of breast tumor, the study was conducted between January 2022 and January 2024</div></div><div><h3>Result</h3><div>Tru-cut biopsy under ultrasound-guidance has shown a high sensitivity and specificity, 98 % and 100 % respectively. Breast carcinoma was confirmed in 106 cases, while benign breast lesions were diagnosed in the remaining nine cases.</div></div><div><h3>Conclusion</h3><div>A Tru-cut biopsy of palpable breast tumors yields comprehensive information with a high sensitivity and specificity, making it a highly reliable diagnostic tool for breast tumors.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100955"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic literature review of MTAP deletions in solid and hematologic Cancers","authors":"Mary C. Clouser ,&nbsp;Mina Suh ,&nbsp;Naimisha Movva ,&nbsp;Janet S. Hildebrand ,&nbsp;Susan T. Pastula ,&nbsp;Martina Schoehl ,&nbsp;Antreas Hindoyan ,&nbsp;Akhila Balasubramanian ,&nbsp;Jon P. Fryzek ,&nbsp;Soo-Ryum Yang","doi":"10.1016/j.ctarc.2025.100966","DOIUrl":"10.1016/j.ctarc.2025.100966","url":null,"abstract":"<div><h3>Background</h3><div>Methylthioadenosine phosphorylase (<em>MTAP)</em> deficiency is observed across multiple cancers and represents an emerging biomarker with therapeutic potential via synthetic lethality with PRMT5 inhibition. This systematic literature review summarizes the prevalence of <em>MTAP</em> deletions or loss of expression and prognostic impacts of <em>MTAP</em> deletions or loss in adult and pediatric patients with specific solid or hematologic cancers.</div></div><div><h3>Methods</h3><div>Following PRISMA methodology, the literature on <em>MTAP</em> deletion or loss in multiple cancer types was reviewed. Prevalence, laboratory testing methods, patient characteristics, and clinical outcomes according to <em>MTAP</em> status were synthesized. Study quality was determined using standard tools.</div></div><div><h3>Results</h3><div>Of the 352 identified studies, 37 reported on <em>MTAP</em>. The majority were retrospective cohorts (N=32; 86%). The most common laboratory test type was NGS, specifically FoundationOne (N=7, 24%). <em>MTAP</em> deletion (loss) prevalence varied across tumor types and were generally lowest in gastric cancer (4%–14%) and highest in glioblastoma (26%–60%). <em>MTAP</em> deletion was correlated with higher prevalence of <em>KRAS</em>. Variation by age, gender, and race/ethnicity were inconsistently reported. Survival outcomes were reported most often for GBM and NSCLC with some studies suggesting worse overall survival among patients with <em>MTAP</em> deletions, although the evidence was heterogeneous.</div></div><div><h3>Conclusion</h3><div>This is the first systematic review to summarize the literature on <em>MTAP</em> deletions or loss of expression across several solid and hematologic cancers. <em>MTAP</em> deletions and/or loss of expression occur in many cancer types, presenting a promising target for pan-cancer therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100966"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy","authors":"Rolando J. Acosta ,&nbsp;Debra A.G. McIntyre ,&nbsp;Joseph C. Murray ,&nbsp;Valsamo Anagnostou ,&nbsp;Julie R Brahmer ,&nbsp;Alexander Meisel ,&nbsp;Ahmet Sezer ,&nbsp;Miranda Gogishvili ,&nbsp;Tamar Melkadze ,&nbsp;Ana Baramidze ,&nbsp;Tamta Makharadze ,&nbsp;Adam Y. He ,&nbsp;Vladimir Jankovic ,&nbsp;Gregory P. Geba ,&nbsp;Asha Pillai ,&nbsp;Frank Seebach ,&nbsp;Petra Rietschel ,&nbsp;Giuseppe Gullo ,&nbsp;Jean-Francois Pouliot ,&nbsp;Young Kim","doi":"10.1016/j.ctarc.2025.100959","DOIUrl":"10.1016/j.ctarc.2025.100959","url":null,"abstract":"<div><h3>Background</h3><div>Patients with a high neutrophil/lymphocyte ratio (NLR) have poor prognosis in non-small cell lung cancer (NSCLC). Limited data are available on the contribution of other immune cells. This analysis assessed the prognostic importance of NLR and other peripheral blood cells in patients with advanced NSCLC receiving the PD-1 inhibitor cemiplimab in 2 large phase III studies.</div></div><div><h3>Methods</h3><div>The impact of baseline immune cells on survival was assessed in patients with complete blood cell counts. Cox proportional hazard regression and Kaplan–Meier methods assessed the relationships between baseline blood cell counts and survival. Data were randomly split into training (70 %) and validation (30 %) cohorts to allow for independent evaluation of the Cox model.</div></div><div><h3>Results</h3><div>Multivariable analyses revealed that a higher NLR (HR: 1.09; 95 % CI: 1.06–1.12, <em>P</em> &lt; .001) and monocytes (HR: 1.49; 95 % CI: 1.15–1.93, <em>P</em> &lt; .001) were strongly associated with an increased risk of death. Higher levels of eosinophils (HR: 0.93; 95 % CI: 0.88–0.99, <em>P</em> &lt; .001) were associated with a reduced risk of death. A calibration curve of observed and predicted probabilities in the unseen test set using independent data revealed that the Cox model was well-calibrated up to a 1-year mortality probability of approximately 30 %. Harrell’s concordance index was 0.61, indicating a modest predictive performance.</div></div><div><h3>Conclusions</h3><div>Our data confirmed the detrimental impact of a high NLR on survival and revealed the importance of monocyte levels in anti-tumor responses, providing useful information to physicians treating advanced NSCLC that may help tailor immunotherapy regimens and provide more accurate prognostic assessments.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100959"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144678839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of adjuvant therapy on survival in treatment of CNS hemangiopericytomas","authors":"Bharti Devnani ,&nbsp;Subhash Gupta ,&nbsp;Vibhay Pareek ,&nbsp;Ahitagni Biswas ,&nbsp;Haresh KP ,&nbsp;Manmohan Singh ,&nbsp;Vivek Tandon ,&nbsp;Ashish Suri ,&nbsp;Pramod Kumar Julka ,&nbsp;Goura Kishor Rath","doi":"10.1016/j.ctarc.2025.100982","DOIUrl":"10.1016/j.ctarc.2025.100982","url":null,"abstract":"<div><h3>Introduction</h3><div>Central nervous system (CNS) Hemangiopericytoma is a rare tumor which account for &lt;0.5% of all CNS tumors. The purpose of this study was to assess the clinical outcomes and the impact of adjuvant treatment on survival.</div></div><div><h3>Materials/ Methods</h3><div>A total of 64 patients histo-pathologically diagnosed as CNS Hemangiopericytoma, treated between 2000 and 2018 with or without adjuvant radiation and chemotherapy, were evaluated for the various survival parameters. Kaplan Meier method was utilized for assessment of the survival outcomes. Treatment and demographic parameters were assessed as prognostic factors for the survival outcomes using Multivariate analysis. The patients were followed up as per the institution protocol.</div></div><div><h3>Results</h3><div>The median follow-up was 50.6 months (range: 8–158 months). The median age was 40 years (range: 8–63 years), with 44 male and 20 female patients. Headache was the most common symptom (46 patients, 71.8%), followed by visual disturbances (18 patients, 28.1%). Tumors were primarily supratentorial (50 patients, 78.1%), with a median diameter of 5 cm (range: 2–7.6 cm). Gross total resection (GTR) was achieved in 40 patients (62.5%). Of the cohort, 34 patients (53.1%) had WHO grade II tumors, and 30 (46.9%) had grade III tumors. Radiation therapy was administered to 54 patients (84.4%) with a median dose of 60 Gy (range: 40–60 Gy), and 8 patients (12.5%) received stereotactic radiation therapy (median: 16.1 Gy). Adjuvant chemotherapy (ifosfamide and epirubicin-based) was given to 40 patients (62.5%). Recurrence occurred in 31 patients (48.4%), with 24 patients (37.5%) experiencing local recurrence and 7 patients (10.9%) developing distant metastases. The median recurrence-free survival (RFS) was 38.4 months, and the median overall survival (OS) was 44 months. Multivariate analysis showed that radiation therapy (<em>p</em> = 0.012), chemotherapy (<em>p</em> &lt; 0.001), and GTR (<em>p</em> = 0.023) significantly reduced recurrence risk.</div></div><div><h3>Conclusion</h3><div>Even though CNS Hemangiopericytoma is a rare disease entity, local and distant recurrences are a cause of concern and require evaluation of role of adjuvant therapy. Our study shows that complete excision followed by adjuvant therapy in the form of radiation therapy and chemotherapy improves the survival in CNS Hemangiopericytoma. Besides the prognostic factors assessed, there is a need for larger prospective study to improve the treatment outcomes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100982"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145057364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of hypoxia on extracellular vesicles in malignant and non-malignant conditions","authors":"Vahid Niazi ,&nbsp;Soudeh Ghafouri-Fard","doi":"10.1016/j.ctarc.2025.100924","DOIUrl":"10.1016/j.ctarc.2025.100924","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) are produced by virtually all types of cells and can be detected in nearly all extracellular places. These particles mediate intercellular communication and transfer their cargo to the recipient cells, inducing a variety of processes in these cells through transmission of several biomolecules such as miRNAs, lncRNAs, other transcripts and a variety of proteins. It has been documented that size, quantity, and expression of biomolecules in the EVs are influenced by the level of oxygen. In fact, hypoxia can affect several cellular processes through modulation of the cargo of these vesicles. Hypoxic exosomes derived from tumor cells have several protumoral effects on the recipient cells, including enhancement of proliferation, migration, and invasion in other tumoral cells, induction of metastasis in distant organs, stimulation of angiogenesis in the endothelial cells, and modulation of macrophage polarization. Hypoxic EVs also contribute to several non-malignant diseases. This review summarizes the effect of hypoxia on EVs cargo in malignant and nonmalignant diseases of different organs.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100924"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"At-home autologous hematopoietic cell transplant for adults with hematological malignancies. How frailty impacts and evolves during HCT procedure. An observational, longitudinal, and prospective study","authors":"Juan Ortiz ,&nbsp;María Teresa Solano ,&nbsp;Cristina Gallego ,&nbsp;Nuria Ballestar ,&nbsp;Noemi de Llobet ,&nbsp;Laia Guardia ,&nbsp;Raquel Salinas ,&nbsp;Alexandra Martínez-Roca ,&nbsp;Beatriz Merchán ,&nbsp;Paola Charry ,&nbsp;Joan Cid ,&nbsp;Miquel Lozano ,&nbsp;Enric Carreras ,&nbsp;Sara Laxe ,&nbsp;Concepción Closa ,&nbsp;María Suárez-Lledó ,&nbsp;Laura Rosiñol ,&nbsp;Carmen Martínez ,&nbsp;Montserrat Rovira ,&nbsp;Francesc Fernández-Avilés ,&nbsp;María Queralt Salas","doi":"10.1016/j.ctarc.2025.100920","DOIUrl":"10.1016/j.ctarc.2025.100920","url":null,"abstract":"<div><h3>Introduction and aims</h3><div>Since April 2021, the frailty state of patients is evaluated routinely in adults undergoing auto-HCT at our institution using the HCT Frailty Scale. The scale categorises each candidate as either fit, pre-fit or frail.</div></div><div><h3>Methods</h3><div>Our study includes 80 consecutive adults with lymphoprolipherative disorders (LPD) and multiple myeloma (MM) undergoing at-home auto-HCT at our institution between June 2021 and June 2023. An initial evaluation of frailty was conducted at first consultation (pre-apheresis), followed by a subsequent evaluation at day +100.</div></div><div><h3>Results</h3><div>The median age was 58 years (range: 19–69), 41 (51.2 %) patients were males, 45 (56.3 %) were diagnosed with MM and 35 with LPD. At the initial consultation, 24 (30.0 %) adults were classified as fit, 48 (60.0 %) as pre-frail, and 8 (10.0 %) as frail. Frail patients were more likely to be older (OR 1.16 <em>P</em> = 0.077), and to have a KPS &lt; 90 % (OR 27, <em>P</em> = 0.012), and also exhibit a higher number of comorbidities (HCT-CI&gt;3: OR 11.9, <em>p</em> = 0.035). However, the underlying diagnosis did not impact the incidence of frailty at the initial consultation (OR 0.99, <em>p</em> = 0.999).</div></div><div><h3>Conclusions</h3><div>There was no association between the duration of at-home transplant hospitalisation and readmissions and the presence of frailty syndrome. Moreover, no patient died due to transplant-related toxicity. The results presented in this study support that at-home auto-HCT can be performed in fit, pre-frail, and frail adults with an experienced and multidisciplinary team. Although conclusions are limited by the reduced sample size, the observed differences on frailty incidences during patient's follow-up support that frailty is dynamic, and potentially amendable with specific interventions.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100920"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the tozzi classification system in diaphragm surgeries for advanced ovarian cancer: Clinical applicability and perioperative outcomes","authors":"Divya Panyam Vuppu ,&nbsp;Priya Bhati ,&nbsp;Saumya Gupta ,&nbsp;Sheejamol V S ,&nbsp;Nitu Puthenveettil","doi":"10.1016/j.ctarc.2025.100958","DOIUrl":"10.1016/j.ctarc.2025.100958","url":null,"abstract":"<div><h3>Background</h3><div>Over 70 % of advanced ovarian cancer cases involve metastasis to the peritoneum, diaphragm, and liver. Standardised diaphragm surgeries are vital for achieving complete cytoreduction and enhancing patient prognosis.</div></div><div><h3>Aim</h3><div>This study evaluates the clinical utility of Tozzi’s classification for diaphragm surgeries and examines perioperative outcomes in advanced ovarian cancer debulking.</div></div><div><h3>Methods</h3><div>Patients who underwent diaphragm surgery during cytoreductive procedures for ovarian cancer were classified using Tozzi’s classification based on disease extent, and liver mobilisation and perioperative outcomes were analysed.</div></div><div><h3>Results</h3><div>Among 38 patients (71 % stage III; 52.6 % interval surgeries), 39.4 % were Type I, 28.9 % Type II, and 31.5 % Type III. Ascites was more common in Type II (77.8 %, <em>p</em> = 0.04), while Type III had more imaging-detected lesions (83.3 %, <em>p</em> = 0.03). Type III surgeries required longer durations (405 ± 136 min, <em>p</em> = 0.04) and more intraoperative interventions (58.3 %, <em>p</em> = 0.01). ICU care was needed in 50 % of cases, with a median stay of two days, mainly for Type III. Pulmonary complications occurred in 10.5 %, and the median hospital stay was six days.</div></div><div><h3>Conclusion</h3><div>Tozzi’s classification predicts surgical complexity and morbidity, particularly for Type III cases, aiding surgical planning and optimising patient outcomes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100958"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of FBXW7 tumor suppressor gene expression and mutations in patients with colorectal cancer: A meta-analysis","authors":"Mohammad Rahmanian ,&nbsp;Iman Elahi Vahed ,&nbsp;Mohammad Shirali ,&nbsp;Raheleh Charmchi ,&nbsp;Amirreza Noura ,&nbsp;Narges Khaleghi gazik ,&nbsp;Reza Senobari ,&nbsp;Zahra Rasouli ,&nbsp;Mohammadsadegh Jafari ,&nbsp;Shokoofeh Noori","doi":"10.1016/j.ctarc.2025.100988","DOIUrl":"10.1016/j.ctarc.2025.100988","url":null,"abstract":"<div><h3>Background</h3><div>Colorectal cancer (CRC) ranks as the second most common cause of cancer-related mortality globally. The tumor suppressor gene FBXW7 is considered to play a key role in determining patient prognosis. This study aims to assess the impact of FBXW7 gene mutations on the prognosis of CRC patients.</div></div><div><h3>Methods</h3><div>A thorough search of different databases, including PubMed, Scopus, Web of Science, and Google Scholar, was performed. Hazard ratios (HRs) along with 95 % confidence intervals (CIs) were utilized to assess the effect of reduced expression or mutation of FBXW7 on disease-free survival (DFS) of CRC patients or their overall survival (OS).</div></div><div><h3>Results</h3><div>This meta-analysis, which included 15 studies, found that low FBXW7 expression or mutations were strongly linked to poorer OS (HR=1.60, 95 % CI= 1.25 to 2.04, I²=65 %) and DFS (HR=2.14, 95 % CI= 1.33 to 3.43, I²=61 %). Sensitivity analyses did not identify any study as a significant source of heterogeneity, and no evidence of publication bias was observed. Studies with ≥36 months of follow-up demonstrated significant OS association (HR=1.62, 95 % CI= 1.20 to 2.17), unlike those with shorter follow-up periods. Both mutation-based studies (HR=1.38, 95 % CI= 1.08 to 1.77) and expression-based studies (HR=2.45, 95 % CI= 1.70 to 3.54) indicated poorer OS, while DFS correlation was significant only in expression-based studies (HR=2.41, 95 % CI= 1.43 to 4.07). The strongest relationship with OS was observed in studies from China (HR=1.99, 95 % CI= 1.27 to 3.12) and the USA (HR=1.63, 95 % CI= 1.17 to 2.26), while the correlation with DFS was mainly seen in non-Chinese studies (HR=3.03, 95 % CI= 1.22 to 7.53).</div></div><div><h3>Conclusion</h3><div>This study suggests that FBXW7 reduced expression or mutations are linked to worse OS and DFS in CRC patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100988"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The cognitive survivorship model: Bridging neuro-oncology and neurology","authors":"Sahar Hemeda ,&nbsp;Mohammed Elmadani ,&nbsp;József Janszky ,&nbsp;Dávid Pintér ,&nbsp;Mate Orsolya ,&nbsp;Norbert Kovács","doi":"10.1016/j.ctarc.2025.100998","DOIUrl":"10.1016/j.ctarc.2025.100998","url":null,"abstract":"<div><div>Cognitive impairment is a prevalent yet often overlooked consequence of cancer and neurodegenerative diseases, substantially impacting the quality of life, daily functioning, and emotional well-being of affected individuals. Despite differing pathologies, both groups exhibit similar cognitive and psychological symptoms, including memory loss, attention deficits, depression, anxiety, and caregiver strain, which frequently persist long after the initial treatment. These symptoms are attributed to shared biological mechanisms, such as neuroinflammation, oxidative stress, and white matter disruption. However, cognitive health has seldom been systematically addressed in cancer or neurology survivorship care, resulting in gaps in long-term support for patients. Recent advances in neuroscience and rehabilitation science, including evidence for non-pharmacological interventions such as cognitive training, mindfulness, and physical activity, underscore the potential for a unified interdisciplinary model. Digital health technologies and telehealth tools have enhanced access and scalability, particularly in remote and underserved populations. In this Opinion article, we propose a Cognitive Survivorship Model (CSM) that integrates oncology and neurology to reframe survivorship from a cognitive health perspective. The model encompasses pillars such as routine cognitive screening, cognitive rehabilitation, psychological support, lifestyle interventions, and caregiver training, supported by digital delivery and policy advocacy. By bridging neuro-oncology and neurology, this model offers a roadmap for person-centred, scalable, and interdisciplinary post-treatment care. We advocate for clinical adoption, policy reform, and further research to validate and implement this model across diverse healthcare systems. Cognitive survivorship must be recognised not as a specialty niche but as a critical component of comprehensive post-diagnosis care.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100998"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing PUMA's lethal potential: BCL-2 family dynamics and novel strategies to combat cancer recurrence.","authors":"Moustafa A Mansour, Mohamed Abdel-Fattah El-Salamoni, Hamdi Nabawi Mostafa","doi":"10.1016/j.ctarc.2025.100975","DOIUrl":"10.1016/j.ctarc.2025.100975","url":null,"abstract":"<p><p>Cancer cells often survive treatment by blocking the natural process of cell death, allowing them to return and grow again. The BCL-2 protein family plays a central role in this process, controlling whether a cell lives or dies. Among its members, the BH3-only proteins initiate the apoptotic cascade in response to cellular stress. PUMA (p53-upregulated modulator of apoptosis), a pro-apoptotic BH3-only protein, is the most potent of its subclass, binding all major anti-apoptotic BCL-2 family members (Bcl-xL, Bcl-2, Mcl-1, and Bcl-w) to counteract their inhibition of Bax and Bak. Upon activation, Bax/Bak form pores in the mitochondrial membrane, releasing apoptogenic factors such as cytochrome c, SMAC, and apoptosis-inducing factor, ultimately triggering caspase-mediated cell death. Due to its upstream role in apoptosis, PUMA deficiency or inhibition by anti-apoptotic proteins promotes cancer development and therapy resistance. Conversely, elevated PUMA expression sensitizes cancer cells to chemo- and radiotherapy. Accumulating evidence positions PUMA as a universal sensor of cell death stimuli and a promising therapeutic target in cancer. This article critically examines PUMA's regulation, function, and potential as a target for cancer treatment.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"100975"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}